Shareholder Votes

Nautilus Biotechnology, Inc. shareholders approved Election of Class II Directors at the 2026-06-17 meeting.

“The following nominees were elected to serve as Class II directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Parag Mallick 67,882,439 2,411,134 14,708,618 Farzad Nazem 67,994,844 2,298,729 14,708,618”

Mirum Pharmaceuticals, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-15 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement for the Annual Meeting.”

Mirum Pharmaceuticals, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-15 meeting.

“The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Mirum Pharmaceuticals, Inc. shareholders approved Election of three Class I directors at the 2026-06-15 meeting.

“The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal.”

Ouster, Inc. shareholders rejected Amendment to Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty at the 2026-06-17 meeting.

“Item 5 - Approval of an amendment to the Company’s Certificate of Incorporation, as amended, to provide for exculpation of officers from breaches of fiduciary duty to the extent permitted by the General Corporation Law of the State of Delaware. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 26,786,230 3,406,515 288,447 15,441,729”

Ouster, Inc. shareholders approved Amendment to Certificate of Incorporation to increase authorized common stock from 100,000,000 to 200,000,000 at the 2026-06-17 meeting.

“Item 4 - Approval of an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock, par value $0.0001 per share, from 100,000,000 to 200,000,000. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 41,616,898 4,013,345 292,678 0”

Ouster, Inc. shareholders approved Advisory (non-binding) approval of the compensation of named executive officers at the 2026-06-17 meeting.

“Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 24,030,941 6,027,161 423,090 15,441,729”

Ouster, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.

“Item 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 45,381,535 332,328 209,058 0”

Ouster, Inc. shareholders approved Election of two Class II directors to serve until the 2029 annual meeting at the 2026-06-17 meeting.

“Item 1 - Election of two Class II directors to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors shall have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Phillip M. Eyler 29,923,243 557,949 15,441,729 Angus Pacala 27,143,496 3,337,696 15,441,729”

Sionna Therapeutics, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.

“2. To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Sionna Therapeutics, Inc. shareholders approved Election of four Class II directors at the 2026-06-17 meeting.

“1. To elect four nominees as Class II directors: H. Edward Fleming, Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D., each to hold office until the Company's Annual Meeting of Stockholders in 2029.”

Structure Therapeutics Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-17 meeting.

“Proposal 3: Advisory vote on the compensation of the Company’s named executive officers On an advisory basis, the shareholders approved the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual General Meeting.”

Structure Therapeutics Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.

“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s shareholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Structure Therapeutics Inc. shareholders approved Election of Directors at the 2026-06-17 meeting.

“Proposal 1: Election of Directors Ted W. Love M.D., Raymond Stevens, Ph.D. and Daniel G. Welch were elected as a Class III directors, to hold office until the 2029 Annual General Meeting of Shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal.”

Burke & Herbert Financial Services Corp. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2026-06-18 meeting.

“Proposal 4: Non-Binding, Advisory Vote on the Frequency of the Advisory Vote on Executive Compensation. Common Stock Votes For 1 Year Votes For 2 Year Votes For 3 Year Votes Abstained Broker Non Votes 4,821,756 73,754 3,934,086 81,584 2,596,996”

Burke & Herbert Financial Services Corp. shareholders approved Advisory vote to approve executive compensation at the 2026-06-18 meeting.

“Proposal 3: Non-Binding, Advisory Vote on Executive Compensation. Common Stock Votes For Votes Against Votes Abstained Broker Non Votes 8,641,259 215,477 54,444 2,596,996”

Burke & Herbert Financial Services Corp. shareholders approved Ratification of appointment of Crowe LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-18 meeting.

“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm. Common Stock Votes For Votes Against Votes Abstained Broker Non Votes 11,440,762 47,736 19,678 —”

Burke & Herbert Financial Services Corp. shareholders approved Election of fourteen directors to serve until the 2027 Annual Meeting at the 2026-06-18 meeting.

“Proposal 1: Election of Directors. Common Stock Director Votes For Votes Against Votes Abstained Broker Non Votes Mark G. Anderson 8,856,538 42,572 12,070 2,596,996 Julian F. Barnwell, Jr. 8,834,663 63,541 12,976 2,596,996 Katherine D. Bonnafé 8,823,567 74,227 13,386 2,596,996 David P. Boyle 8,797,624 100,788 12,768 2,596,996 James M. Burke 8,866,672 33,052 11,456 2,596,996 James P. Geary, II 7,430,854 1,466,164 14,162 2,596,996 Georgette R. George 8,599,011 301,223 10,946 2,596,996 S. Laing Hinson 8,817,673 80,783 12,724 2,596,996 Shawn P. McLaughlin 8,848,237 49,484 13,459 2,596,996 Charles S. Piccirillo 8,839,309 60,925 10,946 2,596,996 Diane Poillon 8,860,980 38,048 12,152 2,596,996 Jose D. Riojas 8,839,140 57,963 14,077 2,596,996 Kristen Snyder 8,861,531 37,472 12,177 2,596,996 David H. Wilson, Sr. 8,886,943 12,582 11,655 2,596,996”

MultiSensor AI Holdings, Inc. shareholders approved Approve an amendment to the Company’s 2023 Incentive Award Plan to increase the number of shares of common stock authorized for issuance thereunder at the 2026-06-12 meeting.

“Proposal 3: To approve an amendment to the Company’s 2023 Incentive Award Plan to increase the number of shares of common stock authorized for issuance thereunder. Votes Cast For Votes Cast Against Abstentions ​ Broker Non-Votes 786,276 142,330 3,335 ​ 374,345”

MultiSensor AI Holdings, Inc. shareholders approved Ratify the appointment of Weaver and Tidwell L.L.P. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-12 meeting.

“Proposal 2: To ratify the appointment of Weaver and Tidwell L.L.P. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes Cast For Votes Cast Against Abstentions 1,234,419 67,318 4,549”

MultiSensor AI Holdings, Inc. shareholders approved Election of directors: Margaret Chu, Stuart ("Trip") V. Flavin III, Daniel Friedberg, David Gow and Petros Kitsos at the 2026-06-12 meeting.

“Proposal 1: To elect Margaret Chu, Stuart (“Trip”) V. Flavin III, Daniel Friedberg, David Gow and Petros Kitsos as directors to hold office until the Company’s annual meeting of stockholders to be held in 2027 and until their respective successors have been duly elected and qualified. Director Nominee Votes Cast For Votes Withheld ​ Broker Non-Votes Margaret Chu 908,326 23,615 ​ 374,345 Stuart (“Trip”) V. Flavin III ​ 906,656 ​ 25,285 ​ 374,345 Daniel Friedberg ​ 907,188 ​ 24,753 ​ 374,345 David Gow ​ 907,082 ​ 24,859 ​ 374,345 Petros Kitsos ​ 853,273 ​ 78,668 ​ 374,345”

Embassy Bancorp, Inc. shareholders approved Ratification of the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-17 meeting.

“The 2026 annual meeting of the shareholders of Embassy Bancorp, Inc. (the “Company”) was held on June 17, 2026. Notice of the meeting was mailed to shareholders of record on or about May 8, 2026, together with proxy solicitation materials prepared in accordance with Section 14(a) of the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder. The annual meeting was held (a) to elect two (2) Class 1 Directors to serve for a 3-year term and until their successors are elected and qualified; and (b) to ratify the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. 1. Election of Directors There was no solicitation in opposition to the nominees of the Board of Directors for election to the Board of Directors and all such nominees were elected. The number of votes cast for or withheld, as well as the number of broker non-votes, for each of the nominees for election to the Boa”

Embassy Bancorp, Inc. shareholders approved Election of two Class 1 Directors to serve for a 3-year term and until their successors are elected and qualified. at the 2026-06-17 meeting.

“The 2026 annual meeting of the shareholders of Embassy Bancorp, Inc. (the “Company”) was held on June 17, 2026. Notice of the meeting was mailed to shareholders of record on or about May 8, 2026, together with proxy solicitation materials prepared in accordance with Section 14(a) of the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder. The annual meeting was held (a) to elect two (2) Class 1 Directors to serve for a 3-year term and until their successors are elected and qualified; and (b) to ratify the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. 1. Election of Directors There was no solicitation in opposition to the nominees of the Board of Directors for election to the Board of Directors and all such nominees were elected. The number of votes cast for or withheld, as well as the number of broker non-votes, for each of the nominees for election to the Boa”

Zentalis Pharmaceuticals, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-16 meeting.

“Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 21,949,844 10,930,673 47,136 16,526,113”

Zentalis Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-16 meeting.

“Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 49,321,951 13,557 118,258 0”

Zentalis Pharmaceuticals, Inc. shareholders approved Election of two Class III directors to serve until the 2029 Annual Meeting of Stockholders at the 2026-06-16 meeting.

“Item 1 — Election of two Class III directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes David Johnson 20,711,869 12,215,784 16,526,113 Jan Skvarka, Ph.D. 23,497,184 9,430,469 16,526,113”

Caribou Biosciences, Inc. shareholders approved Approval of the Adjournment of the 2026 Annual Meeting to a Later Date or Dates, if Necessary, to Permit Further Solicitation and Voting of Proxies in the Event There are not Sufficient Votes in Favor of Proposal 3 or if There are not Sufficient Shares Present to Establish a Quorum. at the 2026-06-17 meeting.

“Proposal 4 - Approval of the Adjournment of the 2026 Annual Meeting to a Later Date or Dates, if Necessary, to Permit Further Solicitation and Voting of Proxies in the Event There are not Sufficient Votes in Favor of Proposal 3 or if There are not Sufficient Shares Present to Establish a Quorum. The stockholders approved the adjournment of the 2026 annual meeting, if necessary, by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 37,615,389 3,418,004 106,383 27,098,425”

Caribou Biosciences, Inc. shareholders rejected Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to Provide for Exculpation of Officers from Certain Breaches of Fiduciary Duty to the Fullest Extent Permitted by the General Corporation Law of the State of Delaware at the 2026-06-17 meeting.

“Proposal 3 - Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to Provide for Exculpation of Officers from Certain Breaches of Fiduciary Duty to the Fullest Extent Permitted by the General Corporation Law of the State of Delaware The stockholders did not approve the above-referenced amendment to the Company's amended and restated certificate of incorporation. The voting results on this proposal were as follows: Votes For Votes Against Votes Abstain Broker Non-Votes 37,483,637 3,513,785 142,354 27,098,425”

Caribou Biosciences, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.

“Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 67,457,482 337,911 442,808 0”

Caribou Biosciences, Inc. shareholders approved Election of Three Class II Directors at the 2026-06-17 meeting.

“Proposal 1 - Election of Three Class II Directors Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2029 annual meeting of stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation, or removal. The voting results on this proposal were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Andrew Guggenhime, M.B.A. 31,554,511 9,585,265 27,098,425 David Johnson, M.B.A. 31,725,652 9,414,124 27,098,425 Nancy Whiting, Pharm.D. 31,694,175 9,445,601 27,098,425”

FS KKR Capital Corp shareholders approved Approval to authorize the Company to issue warrants, options or rights to subscribe for, convert to, or purchase shares of common stock under the 1940 Act Section 61(a)(4) Issuance Proposal at the 2026-06-18 meeting.

“Votes For Votes Against Abstentions Broker Non-Votes 97,297,216 31,396,676 5,615,060 —”

FS KKR Capital Corp shareholders approved Election of Class A Directors: Michael J. Hagan, Jeffrey K. Harrow, James H. Kropp, and Elizabeth J. Sandler at the 2026-06-18 meeting.

“Director Nominee Votes For Votes Withheld Broker Non-Votes Michael J. Hagan 107,888,377 26,420,575 — Jeffrey K. Harrow 93,968,214 40,340,738 — James H. Kropp 118,054,372 16,254,580 — Elizabeth J. Sandler 95,999,861 38,309,091 —”

Adicet Bio, Inc. shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm at the 2026-06-17 meeting.

“Votes For Votes Against Abstain Broker Non-Votes 6,719,352 25,206 1,611 N/A”

Adicet Bio, Inc. shareholders approved Non-Binding Advisory Vote on Compensation of the Company’s Named Executive Officers at the 2026-06-17 meeting.

“Votes For Votes Against Abstain Broker Non-Votes 4,611,540 745,537 4,939 1,384,153”

Adicet Bio, Inc. shareholders approved Election of Class II Director Nominees at the 2026-06-17 meeting.

“Name Votes For Votes Withheld Broker Non-Votes Jeffrey Chodakewitz 4,629,969 732,047 1,384,153 Steve Dubin 4,596,116 765,900 1,384,153 Michael Grissinger 5,257,041 104,975 1,384,153”

Bank First Corp shareholders approved Approval of an amendment to the Company's Articles of Incorporation at the 2026-06-15 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its 2026 Annual Meeting of Shareholders on June 15, 2026 (the “Annual Meeting”). Following is a summary of the proposals that were submitted to the shareholders for approval and a tabulation of the votes with respect to each proposal. Proposal 1 The proposal was to elect as directors the three (3) nominees named in the proxy statement to serve until the 2029 Annual Meeting of Shareholders. Nominee Votes For Vote Against Abstentions Broker Non-Votes Steven M. Eldred 5,239,200 255,872 0 2,528,553 Timothy J. McFarlane 5,255,918 239,154 0 2,528,553 Todd A. Sprang 5,321,610 173,462 0 2,528,553 Proposal 2 The proposal was to ratify the appointment of Forvis Mazars, LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. Votes For Votes Against Abstentions Broker Non-Votes 7,946,631 20,716 56,589 0 Proposal 3 The proposal was an advisory vote on the compensat”

Bank First Corp shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-15 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its 2026 Annual Meeting of Shareholders on June 15, 2026 (the “Annual Meeting”). Following is a summary of the proposals that were submitted to the shareholders for approval and a tabulation of the votes with respect to each proposal. Proposal 1 The proposal was to elect as directors the three (3) nominees named in the proxy statement to serve until the 2029 Annual Meeting of Shareholders. Nominee Votes For Vote Against Abstentions Broker Non-Votes Steven M. Eldred 5,239,200 255,872 0 2,528,553 Timothy J. McFarlane 5,255,918 239,154 0 2,528,553 Todd A. Sprang 5,321,610 173,462 0 2,528,553 Proposal 2 The proposal was to ratify the appointment of Forvis Mazars, LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. Votes For Votes Against Abstentions Broker Non-Votes 7,946,631 20,716 56,589 0 Proposal 3 The proposal was an advisory vote on the compensat”

Bank First Corp shareholders approved Ratification of Forvis Mazars, LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2026 at the 2026-06-15 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its 2026 Annual Meeting of Shareholders on June 15, 2026 (the “Annual Meeting”). Following is a summary of the proposals that were submitted to the shareholders for approval and a tabulation of the votes with respect to each proposal. Proposal 1 The proposal was to elect as directors the three (3) nominees named in the proxy statement to serve until the 2029 Annual Meeting of Shareholders. Nominee Votes For Vote Against Abstentions Broker Non-Votes Steven M. Eldred 5,239,200 255,872 0 2,528,553 Timothy J. McFarlane 5,255,918 239,154 0 2,528,553 Todd A. Sprang 5,321,610 173,462 0 2,528,553 Proposal 2 The proposal was to ratify the appointment of Forvis Mazars, LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. Votes For Votes Against Abstentions Broker Non-Votes 7,946,631 20,716 56,589 0 Proposal 3 The proposal was an advisory vote on the compensat”

Bank First Corp shareholders approved Election of three nominees as directors to serve until the 2029 Annual Meeting of Shareholders at the 2026-06-15 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its 2026 Annual Meeting of Shareholders on June 15, 2026 (the “Annual Meeting”). Following is a summary of the proposals that were submitted to the shareholders for approval and a tabulation of the votes with respect to each proposal. Proposal 1 The proposal was to elect as directors the three (3) nominees named in the proxy statement to serve until the 2029 Annual Meeting of Shareholders. Nominee Votes For Vote Against Abstentions Broker Non-Votes Steven M. Eldred 5,239,200 255,872 0 2,528,553 Timothy J. McFarlane 5,255,918 239,154 0 2,528,553 Todd A. Sprang 5,321,610 173,462 0 2,528,553 Proposal 2 The proposal was to ratify the appointment of Forvis Mazars, LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. Votes For Votes Against Abstentions Broker Non-Votes 7,946,631 20,716 56,589 0 Proposal 3 The proposal was an advisory vote on the compensat”

EBAY INC shareholders rejected Stockholder proposal regarding the Company's special stockholder meeting threshold at the 2026-06-17 meeting.

“4. Proposal 4 – Stockholder Proposal Regarding the Company’s Special Stockholder Meeting Threshold. The Company’s stockholders did not approve the stockholder proposal regarding the ownership requirement for stockholders to call a special meeting. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 156,901,312 210,071,641 1,095,411 34,215,587”

EBAY INC shareholders approved Advisory vote to approve named executive officer compensation at the 2026-06-17 meeting.

“3. Proposal 3 – Advisory Vote to Approve Named Executive Officer Compensation. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 323,495,796 43,613,799 958,769 34,215,587”

EBAY INC shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.

“2. Proposal 2 – Ratification of Appointment of Independent Auditors. The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditors for the Company’s fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 351,593,877 49,885,553 804,521 N/A”

EBAY INC shareholders approved Election of 11 director nominees named in the Proxy Statement at the 2026-06-17 meeting.

“1. Proposal 1 – Election of Directors. Each of the 11 director nominees named in the Proxy Statement was elected to serve until the Company’s 2027 Annual Meeting of Stockholders. The voting results were as follows: Director Name Votes For Votes Against Abstentions Broker Non-Votes Adriane M. Brown 343,443,215 24,215,823 409,326 34,215,587”

Genprex, Inc. shareholders approved Adoption and Approval of Amendment to the Certificate of Incorporation to effect a reverse stock split at the 2026-06-18 meeting.

“Proposal 5. Adoption and Approval of Amendment to the Company’s Amended and Restated Certificate of Incorporation. The amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued shares of common stock, at a specific ratio, ranging from one-for-five (1:5) to one-for-fifty (1:50), at any time prior to December 31, 2027, subject to the Company’s Board of Directors’ determination, in its sole discretion, whether or not to implement the reverse stock split and, if so, at what specific ratio within the foregoing range, without further approval or authorization of the Company’s stockholders, was approved by the stockholders upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 2,941,032 1,592,728 61,268 0”

Genprex, Inc. shareholders approved Approval of the Amended and Restated 2018 Equity Incentive Plan at the 2026-06-18 meeting.

“Proposal 4. Approval of the Company’ s Amended and Restated 2018 Equity Incentive Plan. The proposal to approve the Amended Equity Plan was approved by the stockholders based upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 675,090 337,920 32,396 3,549,622”

Genprex, Inc. shareholders approved Advisory Vote on Compensation of Named Executive Officers at the 2026-06-18 meeting.

“Proposal 3. Advisory Vote on Compensation of Named Executive Officers ( “ NEOs ” ). The votes were cast as follows with respect to the proposal to vote, on an advisory basis, on the compensation of the Company’s NEOs as described in the Company’s Proxy Statement: Votes For Votes Against Abstention Broker Non-Votes 681,841 328,425 35,140 3,549,622”

Genprex, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-18 meeting.

“Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 was approved by the stockholders based upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 4,284,497 254,937 55,594 0”

Genprex, Inc. shareholders approved Election of Directors at the 2026-06-18 meeting.

“Proposal 1. Election of Directors. The Class III director nominees, Jose Antonio Moreno Toscano and Ryan M. Confer, were elected to serve until the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified, or until each such director’s earlier resignation, removal or death. The result of the votes to elect the Class III directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Jose Antonio Moreno Toscano 868,543 176,863 3,549,622 Ryan M. Confer 877,370 168,036 3,549,622”

T-Mobile US, Inc. shareholders approved Advisory vote to approve the compensation provided to the Company’s named executive officers for 2025 at the 2026-06-16 meeting.

“Proposal 3 – Advisory Vote to Approve the Compensation Provided to the Company’s Named Executive Officers for 2025. The compensation provided to the Company’s named executive officers for 2025 was approved by an advisory vote, as set forth below:”

T-Mobile US, Inc. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-16 meeting.

“Proposal 2 – Ratification of the Appointment of Deloitte & Touche LLP. The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 was ratified by the votes set forth below:”